Idiopathic Pulmonary Fibrosis (IPF) & GERD
Trial Objectives
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF.
Who Can Participate
Individuals ages 40-95 who have been diagnosed with IPF may be eligible to participate.
Age: 40-95 Gender: Any
Estimated Time Commitment
5 visits over a 6-month period, visits are every 3 months
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Boehringer Ingelheim
Principal Investigators
Matthew Koslow, MD